Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive update on the development of new XF‑platform drug formulations Collaboration with MedPharm Ltd. delivers data profiling new XF‑platform drug formulations as potential treatments for dermal and ocular infections New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-01-20 02:18:232020-01-24 02:23:26Update on the development of XF drug formulations
Link to Full Article Cambridge, United Kingdom – 14th January, 2020 – Congenica, a digital health company enabling rapid analysis of complex genomic data to improve disease characterization and diagnosis, today announced the launch of Congenica Neuro™, a new application on its clinical decision support platform that facilitates faster, more accurate and comprehensive characterization and diagnosis of epilepsy and […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-01-14 02:14:502020-01-24 02:17:35Congenica launches new application to enable faster analysis of epilepsy and neurodevelopmental disorders
Link to Full Article Product designed to provide safer, more immediate treatment option for patients London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-01-09 02:08:282020-01-24 02:10:55HIKMA AND ARECOR ANNOUNCE EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-USE MEDICINE USING ARESTAT™ TECHNOLOGY
Link to Full Article Study expected to commence in first half of 2020 Valencia, Calif., USA, and Melbourne, Australia, 30 December 2019 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the U.S. Food and […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-30 01:22:532020-01-03 01:29:41AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo
Link to Full Article ARTARMON , Australia, Dec. 20, 2019 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”) today announced The Lancet Neurology journal published results from the U.S. Pivotal Study demonstrating its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System provided long-term, statistically superior, and clinically meaningful pain relief for patients with chronic intractable back and leg pain out […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-21 02:01:152020-01-03 02:02:15Saluda Medical Results of U.S. Evoke Pivotal Study through 12 Months Published in The Lancet Neurology
Link to Full Article Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment Cambridge, UK., 5th December 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-05 02:59:272019-12-30 03:01:17ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING FORMULATION OF INSULIN
Link to Full Article Cambridge, United Kingdom – 3rd December, 2019 – Congenica Ltd, a digital health company enabling rapid analysis of complex genomic data to improve disease characterization and diagnosis, has announced the publication of a new study on the re-annotation of developmental and epileptic encephalopathy-associated genes with significant clinical implications. Developmental and epileptic encephalopathies are a group of rare, […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-03 01:43:562020-01-07 00:17:36Re-annotation of 191 developmental and epileptic encephalopathy-associated genes unmasks de novo variants in SCN1A
Link to Full Article Experienced pharmaceutical executive and medical director with expertise in anti-infective drug development and in-licensing Brighton, United Kingdom – 2 December 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear commercial opportunities and also address the global problem of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-02 01:47:172020-01-03 01:51:14Destiny Pharma appoints Dr Debra Barker as Non-Executive Director
Link to Full Article Liam is Head of Technology Transfer at The Science and Technology Facilities Council (STFC), part of UK Research and Innovation. STFC established The Electrospinning Company in 2010 and have invested and supported the Company since then. After completing his PhD, Liam co-founded and led a company to target an opportunity to […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-01 01:53:222020-01-03 01:54:21Dr Liam Brennan has joined the Board as the STFC Investor Director, replacing Dr Kate Ronayne.
Link to Full Article AVITA Medical secures option for exclusive licensing of emerging technologies Preclinical research will pair AVITA Medical’s Spray-On Skin™ Cells technology and expertise with the Gates Center’s patent pending combined reprogramming and gene editing methodology Valencia, Calif., USA, Melbourne, Australia, and Aurora, Colo., USA, 25 November 2019 — AVITA Medical (ASX: AVH, […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-11-25 00:58:342020-01-03 01:31:53AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa
Update on the development of XF drug formulations
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive update on the development of new XF‑platform drug formulations Collaboration with MedPharm Ltd. delivers data profiling new XF‑platform drug formulations as potential treatments for dermal and ocular infections New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase […]
Congenica launches new application to enable faster analysis of epilepsy and neurodevelopmental disorders
/in CongenicaLink to Full Article Cambridge, United Kingdom – 14th January, 2020 – Congenica, a digital health company enabling rapid analysis of complex genomic data to improve disease characterization and diagnosis, today announced the launch of Congenica Neuro™, a new application on its clinical decision support platform that facilitates faster, more accurate and comprehensive characterization and diagnosis of epilepsy and […]
HIKMA AND ARECOR ANNOUNCE EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-USE MEDICINE USING ARESTAT™ TECHNOLOGY
/in ArecorLink to Full Article Product designed to provide safer, more immediate treatment option for patients London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing […]
AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo
/in Avita MedicalLink to Full Article Study expected to commence in first half of 2020 Valencia, Calif., USA, and Melbourne, Australia, 30 December 2019 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the U.S. Food and […]
Saluda Medical Results of U.S. Evoke Pivotal Study through 12 Months Published in The Lancet Neurology
/in Saluda MedicalLink to Full Article ARTARMON , Australia, Dec. 20, 2019 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”) today announced The Lancet Neurology journal published results from the U.S. Pivotal Study demonstrating its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System provided long-term, statistically superior, and clinically meaningful pain relief for patients with chronic intractable back and leg pain out […]
ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING FORMULATION OF INSULIN
/in ArecorLink to Full Article Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment Cambridge, UK., 5th December 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. […]
Re-annotation of 191 developmental and epileptic encephalopathy-associated genes unmasks de novo variants in SCN1A
/in Congenica, UncategorisedLink to Full Article Cambridge, United Kingdom – 3rd December, 2019 – Congenica Ltd, a digital health company enabling rapid analysis of complex genomic data to improve disease characterization and diagnosis, has announced the publication of a new study on the re-annotation of developmental and epileptic encephalopathy-associated genes with significant clinical implications. Developmental and epileptic encephalopathies are a group of rare, […]
Destiny Pharma appoints Dr Debra Barker as Non-Executive Director
/in Destiny PharmaLink to Full Article Experienced pharmaceutical executive and medical director with expertise in anti-infective drug development and in-licensing Brighton, United Kingdom – 2 December 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear commercial opportunities and also address the global problem of […]
Dr Liam Brennan has joined the Board as the STFC Investor Director, replacing Dr Kate Ronayne.
/in ElectrospinningLink to Full Article Liam is Head of Technology Transfer at The Science and Technology Facilities Council (STFC), part of UK Research and Innovation. STFC established The Electrospinning Company in 2010 and have invested and supported the Company since then. After completing his PhD, Liam co-founded and led a company to target an opportunity to […]
AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa
/in Avita MedicalLink to Full Article AVITA Medical secures option for exclusive licensing of emerging technologies Preclinical research will pair AVITA Medical’s Spray-On Skin™ Cells technology and expertise with the Gates Center’s patent pending combined reprogramming and gene editing methodology Valencia, Calif., USA, Melbourne, Australia, and Aurora, Colo., USA, 25 November 2019 — AVITA Medical (ASX: AVH, […]